The 5 drugs tracked here made $35.1B of AbbVie’s 2025 revenue (57%) and lose US exclusivity by 2037. Since 2023, AbbVie has closed 5 acquisitions of $1B or more, worth $33.2B in total. Products from those deals brought in $690M in 2025.
Bars are each drug's 2025 sales as a share of AbbVie’s total revenue ($61.2B). Only drugs tracked here are counted, so full exposure can be higher. Tap a bar for the drug's page.
| Closed | Company bought | Value | Area | What it brought | At closing |
|---|---|---|---|---|---|
| Feb 2024 | ImmunoGenAbbVie, November 2023 · AbbVie, February 2024 | $10.1B | Oncology | Elahere, an antibody-drug conjugate for ovarian cancer2025 sales: Elahere $690M AbbVie 10-K 2025 | Approved product |
| Aug 2024 | Cerevel TherapeuticsAbbVie, December 2023 · AbbVie, August 2024 | $8.7B | Neuroscience | Tavapadon for Parkinson's disease (Phase 3) and emraclidine for schizophrenia | Pipeline only |
| Dec 2024 | Aliada TherapeuticsAbbVie, October 2024 | $1.4B | Neuroscience | ALIA-1758, an early antibody for Alzheimer's disease | Pipeline only |
| Aug 2025 | Capstan TherapeuticsAbbVie, June 2025 · AbbVie 10-K 2025 | $2.1B | Immunology | CPTX2309, an early in vivo CAR-T therapy for autoimmune disease | Pipeline only |
| Sep 2026 | Apogee TherapeuticsAbbVie, June 2026 · AbbVie, September 2026 | $10.9B | Immunology | Zumilokibart, a long-acting IL-13 antibody for atopic dermatitis, and asthma programs | Pipeline only |
| 5 counted | $33.2B | ||||
Acquisitions of whole companies closed since January 2023 with a headline price of $1B or more. Values are the price AbbVie announced, excluding milestone payments unless noted. Licensing deals are not included. Compare all 65 deals →
| Area | At risk by 2037 | Acquisitions since 2023 |
|---|---|---|
| Immunology | $25.9B | $13.0B |
| Oncology | $5.7B | $10.1B |
| Neuroscience | $3.6B | $10.1B |
Immunology is where AbbVie has the most revenue at risk and where it has spent the most on acquisitions. At risk is 2025 sales of tracked drugs losing US exclusivity by 2037; acquisitions are the headline value of counted deals closed since 2023.
The two figures measure different things. Revenue at risk is what the drugs earned in 2025. A deal's value is what AbbVie paid, not the sales it will bring in. Only one of the 5 companies it bought was already selling an approved product at closing (ImmunoGen); the rest brought pipeline drugs whose sales are years away and may never arrive. The closest like-for-like figure is sales of the products AbbVie bought: $690M in 2025, against $35.1B of 2025 sales losing US exclusivity by 2037. So this page shows the figures side by side rather than claiming how much of the gap the deals fill.
Revenue: AbbVie FY2025. Drug sales and dates are sourced on each drug's page; each deal links to AbbVie’s announcement or filing in the table above.
See all 63 drugs on the patent cliff →Hetero's capsules are approved, but AbbVie still expects no US generic before 30 March 2032. FDA Orange Book
AbbVie settled with every generic filer. Analysts had modeled US exclusivity ending in 2032. Fierce Pharma